Estudio comparativo de la rentabilidad de la Empresa San Farma de los periodos 2020 y 2021.

The pharmaceutical distributor Sanfarma began operations on August 11, 2015 with the RUC 12053337601, under the name of Sandoya Valero Elsy Carlota. For the comparative study of the business profitability of Sanfarma for the period 2020 - 2021, it is important to highlight that it is an industry model that dominates the commercialization of pharmaceutical products or medicines at the national level, including the existence of monopolistic chains that cover a much of the market. This is the case of Sanfarma, the impact of the pandemic on its profits will be studied through a comparison of the years 2020 and 2021. It is important to know the status and results of the pharmaceutical product distributor Sanfarma, suggest different contexts or methods, Track whether the organization was profitable during the study period, plus what segmentation and analytics used will yield appropriate results by using different formulas. Information on economic indicators should be taken into account, since it will be of great help for the evaluation of the pharmaceutical line, since it may be sufficient to achieve stability or constant profits. The impact of sales on a pharmaceutical distributor's bottom line is high, and despite a sharp drop in initial earnings due to restrictions imposed by forced closures and tightening industry conditions, earnings rise significantly as of as operating restrictions apply. strategies. The owner said that the impact of the prices of the products/services on the pharmacy's income was moderate, given the high cost of some medicines and consumables necessary for the pandemic.

• Hovedforfatter: León Varas, María Fernanda (author)
• Format: bachelorThesis
• Udgivet: 2022
• Fag: Rentabilidad; Ganancias; Ingresos; farmacéutica; Industria
• Online adgang: http://dspace.utb.edu.ec/handle/49000/12794